PKG II inhibits PDGF-BB triggered biological activities by phosphorylating PDGFRβ in gastric cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Receptor tyrosine kinases (RTKs) are crucial in cancer signaling.
• Platelet-derived growth factor receptor beta (PDGFRβ) is implicated in gastric cancer progression.
• The role of protein kinase G II (PKG II) in PDGFRβ regulation remained unclear.

Purpose of the Study:

• To investigate the regulatory effect of PKG II on PDGFRβ activation in gastric cancer.
• To elucidate the downstream signaling pathways affected by PKG II and PDGFRβ.
• To identify the specific site of PDGFRβ phosphorylation by PKG II.

Main Methods:

• Cell proliferation (CCK8) and migration (Transwell) assays.
• Immunoprecipitation and Western blotting to assess protein interactions and phosphorylation.
• Site-directed mutagenesis of PDGFRβ phosphorylation sites (Ser643 and Ser712).

Main Results:

• PDGF-BB stimulation increased gastric cancer cell proliferation and migration.
• Activated PKG II reversed PDGF-BB-induced proliferation and migration.
• PKG II directly bound and phosphorylated PDGFRβ, inhibiting its activation and downstream MAPK/ERK and PI3K/Akt pathways.
• Mutation of Ser712, but not Ser643, abolished PKG II's inhibitory effect, identifying Ser712 as the key phosphorylation site.

Conclusions:

• PKG II inhibits PDGFRβ activation in gastric cancer.
• Phosphorylation of PDGFRβ at Ser712 by PKG II is critical for this inhibition.
• PKG II represents a potential therapeutic target for gastric cancer by modulating PDGFRβ signaling.